2-(2-oxoethyl)cyclopentanone | 140238-58-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-oxoethyl)cyclopentanone
• 英文别名: 2-(2-oxocyclopentyl)acetaldehyde
• CAS: 140238-58-0
• 化学式: C₇H₁₀O₂
• 分子量: 126.155
• InChiKey: IZKFOBJJTXXUCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-oxoethyl)cyclopentanone 在 吡啶 、 4-二甲氨基吡啶 、 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 为溶剂， 反应 29.0h， 生成 (1R^*,3R^*,5R^*)-10-Acetoxy-11-(methoxycarbonyl)-2-oxatricyclo<5.3.1.0^1,5>undec-10-ene
  参考文献：
  名称：

  Neighboring group participation in Lewis acid-promoted [3 + 4] and [3 + 5] annulations. The stereocontrolled synthesis of tricyclic ethers

  摘要：

  A variety of 1,4- and 1,5-keto aldehydes derived from cycloalkanes are coupled with the bis(trimethylsilyl) enol ether of methyl acetoacetate in the presence of either TMSOTf or TrSbCl6 to generate tricyclic ethers. The reactions proceed with excellent regiochemical control by a mechanism involving neighboring group participation. This mechanism involves initial formation of a bicyclic oxocarbenium ion intermediate from the keto aldehyde substrates. The geometries of selected bicyclic intermediates have been optimized using the AM1 method allowing successful prediction of the stereochemical outcomes in the cyclization in most cases. Epimerization of alpha-chiral keto aldehyde substrates does not appear to occur in these Lewis acid-promoted annulation reactions.

  DOI：

  10.1021/jo00074a018
• 作为产物：
  描述：

  (1RS,2RS,4SR)-7,7-dimethoxybicyclo[2.2.1]heptan-2-ol 在 盐酸 作用下， 反应 6.0h， 以60%的产率得到2-(2-oxoethyl)cyclopentanone
  参考文献：
  名称：

  酸催化 7,7-二甲氧基降冰片醇的裂解。快速进入 5-取代 2-环戊烯酮

  摘要：

  报道了一种从 7,7-二甲氧基 5-降冰片烯-2-醇及其衍生物的酸催化碎裂合成 2-环戊烯酮的简便方法。

  DOI：

  10.1055/s-1997-703

文献信息

• Visible-Light Photocatalytic Preparation of 1,4-Ketoaldehydes and 1,4-Diketones from α-Bromoketones and Alkyl Enol Ethers
  作者：William H. García-Santos、Jeferson B. Mateus-Ruiz、Alejandro Cordero-Vargas

  DOI：10.1021/acs.orglett.9b01275

  日期：2019.6.7

  A Ru2+-photocatalyzed, visible-light-mediated ATRA reaction for the straightforward preparation of 1,4-ketoaldehydes, 1,4-diketones, and 1,4-ketoesters, which are of difficult access by other means, is reported herein. This method employs readily accessible α-bromoketones and alkyl vinyl ethers as starting materials, allowing the construction of secondary, tertiary, and challenging quaternary centers

  本文报道了Ru 2+光催化的可见光介导的ATRA反应，用于直接制备难以通过其他方式获得的1,4-酮醛，1,4-二酮和1,4-酮酸酯。 。该方法采用易于获得的α-溴代酮和烷基乙烯基醚作为起始原料，从而可以构建仲，叔和具有挑战性的季中心。另外，通过将该方法应用于取代的吡咯的构造来说明该方法的合成有用性。
• Elimination-free powder coating crosslinking agents
  申请人：——

  公开号：US20040133035A1

  公开（公告）日：2004-07-08

  The present invention relates to novel blocked, elimination-free polyurethane (PUR) crosslinking agents, to a process for their preparation and to their use as starting components for the production of polyurethane plastics, especially as crosslinking agents for thermally crosslinkable powder coatings.

  本发明涉及新型的无阻聚氨酯（PUR）交联剂，涉及它们的制备过程以及它们作为聚氨酯塑料的生产起始组分的用途，特别是作为热交联粉末涂料的交联剂。
• TRIAZOLOPYRIDINE COMPOUNDS
  申请人：Hermann Johannes Cornelius

  公开号：US20120309746A1

  公开（公告）日：2012-12-06

  The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用以下式I的新型三唑吡啶衍生物： 其中所有变量取代基的定义如本文所述，这些化合物是SYK抑制剂，可用于治疗自身免疫和炎症性疾病。
• Amine Compounds
  申请人：Ohmori Yutaka

  公开号：US20080200535A1

  公开（公告）日：2008-08-21

  There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

  提供了一种化合物，具有抑制免疫反应并减少不良药物反应的活性，该化合物在化疗中用于预防或治疗各种自身免疫性疾病，包括系统性红斑狼疮、慢性类风湿关节炎、I型糖尿病、炎症性肠病、胆汁性肝硬化、葡萄膜炎、多发性硬化或其他疾病，慢性炎症性疾病，癌症，淋巴瘤或白血病，器官或组织移植的抗性或对移植的排斥。提供了具有S1P1/Edg1受体激动剂作用的新型胺类化合物，可能是这些化合物的立体异构体或消旋体，或这些化合物、立体异构体或消旋体的药理学上可接受的盐、水合物或溶剂合物，或这些化合物、立体异构体、消旋体、盐、水合物或溶剂的前药。
• PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS
  申请人：Kohli Steck Rachel

  公开号：US20100234485A1

  公开（公告）日：2010-09-16

  The present invention provides organometallic latent catalyst compounds, which are suitable as catalysts in polyaddition or polycondensation reactions which are catalysed by a Lewis acid type catalyst, in particular for the crosslinking of a blocked or unblocked isocyanate or isothiocyanate component with a polyol or polythiolto form a polyurethane (PU).

  本发明提供了有机金属潜伏催化剂化合物，适用于由Lewis酸类催化剂催化的聚加成反应或缩聚反应中作为催化剂，特别是用于将受阻或未受阻的异氰酸酯或异硫氰酸酯组分与多元醇或多硫醇交联以形成聚氨酯（PU）。